XSpray Launches GMP Production Facility

XSpray Microparticles has launched its new GMP production facility in Malmo, Sweden. With the introduction of this new plant, XSpray is expected to provide quality drug particles and powders for use in the clinical studies.

XSpray claims that its RightSize Particle Manufacturing Technology is a ground-breaking solution for pharmaceutical particle development and production based on supercritical fluid technology. It overcomes many of the drawbacks of traditional micronization and is well suited to demanding applications, such as inhaled compounds, sparingly soluble compounds and biopharmaceuticals. Along with offering all the advantages of earlier supercritical fluid technologies, it also enables full scalability.

The new GMP facility has been developed in collaboration with Galenica. Manufacturing will be carried out by Galenica at the company’s GMP suites in Malmo, Sweden.

Per Andersson, CEO of XSpray, said: “We are extremely pleased to have this facility in place. Not only does it mean that we can now satisfy our customers’ needs for GMP material but it is also proof of the scale-up capability of the technology. As such, it is an important step towards developing full pharmaceutical manufacturing capabilities. We are also very pleased with the collaboration with Galenica. We have every confidence that our customers will benefit from an extremely high quality, professional service.”